Clinical trial · Interventional
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma
NCT01290406CI-TRIAL-00007231withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open label and single arm study to investigate the safety and efficacy of BEZ235 in adult women with endometrial carcinoma whose disease progressed (or recurred) while on or after first-line antineoplastic treatment for advanced endometrial carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BEZ235 | Drug | Dactolisib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BEZ235
- interventionNames
- Drug: BEZ235
Primary outcomes (1)
- measure
- assess the efficacy of BEZ235 as measured by Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)
- timeFrame
- every 8 weeks
Secondary outcomes (2)
- measure
- evaluate additional efficacy parameters (e.g. Disease Control Rate, Progression-Free Survival)
- timeFrame
- every 8 weeks
- measure
- evaluate safety of BEZ235. Safety assessments will include vital signs, laboratory tests, and frequency of adverse events (non-serious and serious).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female ≥ 18 years * Histological confirmed diagnosis of advanced endometrial carcinoma with available tissue specimen, either archival tissue or fresh formalin fixed tumor biopsy * Objective and radiologically confirmed progression of disease after prior first-line treatment * Recovery (to grade ≤ 1) from all clinically significant toxicities related to prior therapies (except alopecia) with adequate bone marrow and organ functions * At least one measurable lesion as per RECIST * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Exclusion Criteria: * Previous treatment with PI3K and/or mammalian Target Of Rapamycin (mTOR) inhibitors * More than one line of prior treatment for advanced or metastatic disease * Active uncontrolled or symptomatic Central Nervous System (CNS) metastases * Concurrent malignancy or malignancy in the last 3 years prior to start of study treatment * Wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to enrollment in this study * Active cardiac disease (e.g. Left Ventricular Ejection Fraction (LVEF) \< 50%, Q-T interval corrected for heart rate (QTcF) \> 480 msec on screening Electrocardiogram (ECG), unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias) * Inadequately controlled hypertension * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235 * Drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of CYP3A4, warfarin and coumadin analogues, Luteinizing Hormone-Releasing Hormone (LHRH) agonists * Pregnant or nursing (lactating) woman Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.